News Release

The Use of HemogloBind™ in Proteomic Analysis of Programmed Death of Red Blood Cells

MONMOUTH JUNCTION, NJ , December 13, 2023 -- Biotech Support Group reports on a journal article describing the simplicity and efficiency of HemogloBind™, to remove Hemoglobin interference prior to LC-MS proteomic analysis of red blood cells.

The citation is:

Chen, Yaozhen, et al. "Noncanonical NLRP3 Inflammasome Activation Elicits the Programmed Death of Red Blood Cells ." Available at SSRN 4626203 .

The canonical complement-mediated lysis of red blood cells (RBCs) leads to serious pathogenesis. To seek more efficient therapy, the authors investigated the intracellular events in RBCs following complement activation. They demonstrate that complement-induced hemolysis was caspase-8-dependent. So to investigate the downstream signaling of caspase-8 in mature RBCs, label free proteomic analysis was conducted. The article states “RBC lysates (control and complement-treated groups) … Hemoglobin was removed by adding 250 µl of HemogloBind suspension (Biotech Support Group) to the cell lysate. …Subsequently, samples without hemoglobin were analyzed using chromatography-tandem mass spectrometry (LC-MS/MS)”. This analysis identified proteins with both upregulated and downregulated expressions in response to complement activation and revealed a significant involvement of biological processes and pathways associated with cytoskeleton organization and actin filament assembly dynamics. Overall, the findings unveil a programmed death cascade in mature RBCs, which may have implications for the treatment of hemolytic disorders.

“I am pleased to see that the use of HemogloBind™ was necessary to remove such a highly abundant protein – Hemoglobin, so that proteomic analysis on red cell hemolysates became possible. The observations here demonstrate how HemogloBind™ can be used to uncover proteome differences between two red cell samples types, the control and complement-treated groups. ” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Click here for more information on HemogloBind™

Click here for more information on all of our Hemoglobin Removal products

Keywords: Hemoglobin depletion, HemogloBind™, red cell proteomics, NLRP3, inflammasome, caspase-8, spectrin, programmed cell death, red blood cells, complement hemolysis

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for expanding proteomic analysis. Following a tiered business strategy, the company continues its growth in the consumable research products area. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite ™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance and family specific proteome enrichment. For more information, go to http://www.biotechsupportgroup.com

For business development contact: Matthew Kuruc
732-274-2866 mkuruc@biotechsupportgroup.com